Skip to main content
PRGO
NYSE Life Sciences

Perrigo Appoints Two Experienced Independent Directors to Board, Expanding Size to 10

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$10.39
Mkt Cap
$1.438B
52W Low
$9.225
52W High
$28.435
52W Position info
13% above low
Off High info
63% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

PRGO is trading near its 52-week low of $9.225 (13% above the low).

Summary

Perrigo appointed Salman Amin and Omer Gajial as independent directors, expanding its board to 10 members, a move aimed at strengthening governance and strategic oversight following recent leadership changes and financial setbacks.


Key Events · Executive and Board Changes · PRGO

  • Two New Independent Directors Appointed

    Salman Amin and Omer Gajial have been appointed as independent directors to the Board, effective June 30, 2026.

  • Board Size Expansion

    The Board of Directors increased its size from 8 to 10 members to accommodate the new appointments.

  • Experienced Leadership Added

    Mr. Amin brings over 30 years of global consumer products experience (ex-CEO of pladis Global, senior roles at PepsiCo and P&G), while Mr. Gajial has extensive retail, e-commerce, and consumer health expertise (CEO of GoTo Foods, ex-Albertsons EVP).

  • Strengthening Governance Post-CEO Departure

    These appointments follow the immediate resignation of CEO Patrick Lockwood-Taylor on June 8, 2026, and a significant net loss reported for Q1 2026, indicating a proactive effort to bolster leadership and strategic oversight.


Analysis · PRGO · Life Sciences

Perrigo has appointed two highly experienced independent directors, Salman Amin and Omer Gajial, to its Board, increasing the board size from 8 to 10 members. This move is significant as it follows the recent resignation of the CEO and a challenging first quarter with substantial losses. The new directors bring valuable expertise in global consumer products, retail, e-commerce, and digital transformation, which can help strengthen governance and strategic direction during a period of leadership transition and financial challenges.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRGO was trading at $10.39 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $9.23 to $28.44. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRGO - Latest Insights

PRGO
Nov 04, 2026, 12:54 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.47
Real-time Price: $16.28 info
Change: -$0.1849 (-1%) info
Market Cap: $2.268B info
PRGO
Nov 04, 2026, 6:44 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.15
Real-time Price: $16.28 info
Change: +$0.1301 (+0.81%) info
Market Cap: $2.268B info
PRGO
Nov 04, 2026, 6:41 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $16.15
Real-time Price: $16.28 info
Change: +$0.1301 (+0.81%) info
Market Cap: $2.268B info
PRGO
Nov 04, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.70
Real-time Price: $16.28 info
Change: +$0.5801 (+4%) info
Market Cap: $2.268B info
PRGO
Oct 29, 2026, 9:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.95
Real-time Price: $16.28 info
Change: +$0.3301 (+2%) info
Market Cap: $2.268B info